A Phase Ib/II, Multicenter, Single Arm, Open-Label Study, To Evaluate the Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects With Acute Myeloid Leukemia Who Are 60 Years or Older - The BATTLE Study

Trial Profile

A Phase Ib/II, Multicenter, Single Arm, Open-Label Study, To Evaluate the Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects With Acute Myeloid Leukemia Who Are 60 Years or Older - The BATTLE Study

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Atezolizumab (Primary) ; BL 8040 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Acronyms BATTLE
  • Sponsors BioLineRx
  • Most Recent Events

    • 08 Aug 2017 This trial is part of MORPHEUS, Roche's Novel Cancer Immunotherapy Development Platform, according to a BioLineRx media release.
    • 22 May 2017 According to a BioLineRx media release, company today announced the filing of regulatory submissions required to commence this study.
    • 14 May 2017 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top